News | April 05, 2021
Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
This facility marks a significant milestone in transforming the global food industr
Subscribe To Our Newsletter & Stay Updated
